Angiotensin receptor blockers: How important is selectivity?

被引:50
作者
Siragy, HM [1 ]
机构
[1] Univ Virginia, Dept Internal Med, Charlottesville, VA 22908 USA
关键词
angiotensin receptor blockers; hypertension; diabetes; heart failure; AT(2) receptor;
D O I
10.1016/S0895-7061(02)02280-X
中图分类号
R6 [外科学];
学科分类号
1002 ; 100210 ;
摘要
During the last decade, angiotensin-receptor blockers have established themselves as effective antihypertensive agents with impressive safety profile and placebo-like tolerability. Additionally, these compounds provide benefits beyond the reduction in blood pressure, in conditions such as heart failure and in patients with type 2 diabetes and renal insufficiency. It is tempting to group all angiotensin-receptor blockers together as a class, but a closer look reveals differences, for example, in chemical structure, metabolism, dissociation rates, and receptor affinities. Recent findings on the respective roles of the angiotensin recep-tors AT(1) and AT(2) have raised the possibility that the degree of selectivity for AT, over AT, might affect the performance of the drug. This review attempts to put the concept of selectivity in context and to assess the potential benefits in different organs, with focus on the kidney, endothelium and the heart. Am J Hypertens 2002;15: 1006-1014 (C) 2002 American Journal of Hypertension, Ltd.
引用
收藏
页码:1006 / 1014
页数:9
相关论文
共 101 条
[1]   HFSA guidelines for management of patients with heart failure caused by left ventricular systolic dysfunction - Pharmacological approaches [J].
Adams, KF ;
Baughman, KL ;
Dec, WG ;
Elkayam, U ;
Forker, AD ;
Gheorghiade, M ;
Hermann, D ;
Konstam, MA ;
Liu, P ;
Massie, BM ;
Patterson, JH ;
Silver, MA ;
Stevenson, LW ;
Feldman, AM ;
Cohn, JN ;
Francis, GS ;
Greenberg, B ;
Konstam, MA ;
Leier, C ;
Lorell, BH ;
Packer, M ;
Pitt, B ;
Silver, MA ;
Sonnenblick, E ;
Strobeck, J ;
Walsh, R ;
Yusuf, S .
PHARMACOTHERAPY, 2000, 20 (05) :495-522
[2]   Pharmacological modulation of spontaneous renal blood flow dynamics [J].
Ajikobi, DO ;
Novak, P ;
Salevsky, FC ;
Cupples, WA .
CANADIAN JOURNAL OF PHYSIOLOGY AND PHARMACOLOGY, 1996, 74 (08) :964-972
[3]   Role of angiotensin II and bradykinin in experimental diabetic nephropathy - Functional and structural studies [J].
Allen, TJ ;
Cao, ZM ;
Youssef, S ;
Hulthen, UL ;
Cooper, ME .
DIABETES, 1997, 46 (10) :1612-1618
[4]  
Amuchastegui SC, 1998, J AM SOC NEPHROL, V9, P1948
[5]   Possible role of P-450 metabolite of arachidonic acid in vasodilator mechanism of angiotensin II type 2 receptor in the isolated microperfused rabbit afferent arteriole [J].
Arima, S ;
Endo, Y ;
Yaoita, H ;
Omata, K ;
Ogawa, S ;
Tsunoda, K ;
Abe, M ;
Takeuchi, K ;
Abe, K ;
Ito, S .
JOURNAL OF CLINICAL INVESTIGATION, 1997, 100 (11) :2816-2823
[6]  
ARZILLI F, 1997, HIGH BLOOD PRESS, V6, P153
[7]   AT2 receptor stimulation enhances antihypertensive effect of AT1 receptor antagonist in hypertensive rats [J].
Barber, MN ;
Sampey, DB ;
Widdop, RE .
HYPERTENSION, 1999, 34 (05) :1112-1116
[8]   Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension: efficacy, tolerability and safety compared to an angiotensin-converting enzyme inhibitor, lisinopril [J].
Black, HR ;
Graff, A ;
Shute, D ;
Stoltz, R ;
Ruff, D ;
Levine, J ;
Shi, Y ;
Mallows, S .
JOURNAL OF HUMAN HYPERTENSION, 1997, 11 (08) :483-489
[9]   Role of type 1 and type 2 angiotensin receptors in angiotensin II-induced cardiomyocyte hypertrophy [J].
Booz, GW ;
Baker, KM .
HYPERTENSION, 1996, 28 (04) :635-640
[10]  
Bremner AD, 1997, CLIN EXP HYPERTENS, V19, P1263